Acer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACER, and when can generic versions of ACER drugs launch?
ACER has three approved drugs.
There are eleven US patents protecting ACER drugs.
There are one hundred and forty-seven patent family members on ACER drugs in thirty-five countries and seventy-three supplementary protection certificates in ten countries.
Summary for Acer
| International Patents: | 147 |
| US Patents: | 11 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Acer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-004 | Dec 22, 2022 | RX | Yes | No | 11,154,521 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-002 | Mar 3, 2017 | DISCN | Yes | No | 9,539,302 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-002 | Mar 3, 2017 | DISCN | Yes | No | 11,419,914 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-006 | Dec 22, 2022 | RX | Yes | Yes | 11,433,041 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-006 | Dec 22, 2022 | RX | Yes | Yes | 11,154,521 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-002 | Dec 22, 2022 | RX | Yes | No | 11,202,767 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,574,622 | ⤷ Sign Up |
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-002 | Mar 3, 2017 | 7,579,321 | ⤷ Sign Up |
| Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,877,230 | ⤷ Sign Up |
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-001 | Mar 3, 2017 | 7,405,203 | ⤷ Sign Up |
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-002 | Mar 3, 2017 | 7,405,203 | ⤷ Sign Up |
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-001 | Mar 3, 2017 | 7,799,761 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Acer Drugs
Supplementary Protection Certificates for Acer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1912999 | 1490062-5 | Sweden | ⤷ Sign Up | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| 2822954 | 18C1035 | France | ⤷ Sign Up | PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
| 1758590 | 2017C/063 | Belgium | ⤷ Sign Up | PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612 |
| 1856135 | SPC/GB20/016 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTERED: UK EU/1/19/1405 (NI) 20200113; UK PLGB 12930/0022 20200113; UK PLGB 12930/0023 20200113 |
| 2932970 | 18C1043 | France | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518 |
| 1948158 | 1690020-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
